Bonnie Gillis

Articles

Sequencing Chemo After Radium-223 Safe in mCRPC

October 26th 2015

Determining the optimal sequencing of novel agents with standard chemotherapy has become a key issue in the management of castration-resistant prostate cancer.

Accelerated Partial Breast Irradiation Demonstrates Efficacy in Low-Risk Breast Cancer

October 25th 2015

Rates of overall survival, disease-free survival, and local control were found to be comparable in select patients with early-stage breast cancer who underwent accelerated partial breast irradiation using multicatheter brachytherapy versus conventional whole breast irradiation.

Renal Cell Carcinoma Vaccine Fails to Improve Outcomes

October 15th 2015

The IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.

Tasquinimod Discontinuation in mCRPC Discussed at 2015 ECC

September 30th 2015

Tasquinimod, a drug that showed great promise in phase II trials, failed to improve overall survival in a phase III trial in men with treatment-naïve metastatic castration-resistant prostate cancer.

IDH2 Inhibitor Shows Promise in AML

July 18th 2014

An early study presented at the 2014 AACR Annual Meeting showed promise for a new targeted therapy for acute myeloid leukemia

Dacomitinib Shows Promise in Head and Neck Cancer

July 7th 2014

Dacomitinib holds promise for the treatment of metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).

Novel Epigenetic Therapy Shows Clinical Activity in Hematologic Malignancies

July 2nd 2014

Preliminary evidence supports the use of bromodomain inhibitors in hematologic malignancies, including acute leukemia (mainly acute myelogenous leukemia) and other hematological malignancies, including diffuse large B-cell lymphoma and multiple myeloma.

Blood Test Predicts Resistance to Enzalutamide in mCRPC

June 23rd 2014

It may be possible to predict which men with metastatic castration-resistant prostate cancer will not respond to enzalutamide by using a simple blood test to detect the presence of AR-V7 in circulating tumor cells.

Anti-CD20 Antibodies Continue to Improve Outlook in CLL

January 16th 2014

The FDA approval of two anti-CD20 antibodies-ofatumumab and, recently, obinotuzumab-has greatly advanced the outlook for managing chronic lymphocytic leukemia.

Treatment Advances Bring New Hope in Gastric Cancer

January 7th 2014

Several new drugs have recently shown promise for the treatment of gastric cancer, including rilotumumab, ramucirumab, and anti-HER2 agents, according to a presentation at the 2013 Chemotherapy Foundation Symposium.

x